Bavarian Nordic Issues Financial Calendar for 2017
(Thomson Reuters ONE) -
COPENHAGEN, Denmark, September 13, 2016 - Bavarian Nordic A/S (OMX: BAVA, OTC:
BVNRY) today announced its financial calendar for the year 2017.
March 15, 2017 2016 Annual Report
April 25, 2017 Annual General Meeting
May 4, 2017 First quarterly report (Q1) for the three-month period ended
31 March 2017
August 25, 2017 Half-year report (Q2) for the six-month period ended 30 June
2017
November 8, 2017 Third quarterly report (Q3) for the nine-month period ended
30 September 2017
Pursuant to Article 12 of the Articles of Association, shareholders who wish to
submit a request for proposals for consideration at the Annual General Meeting
must lodge this with the Company no later than Wednesday, March 15, 2017.
Moreover, it should be noted that Bavarian Nordic in a period of two weeks
before planned publication of quarterly reports (silent periods), will not
comment specifically on developments or financial issues and expectations.
About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the
development, manufacturing and commercialization of cancer immunotherapies and
vaccines for infectious diseases, based on the Company's live virus vaccine
platform. Through long-standing collaborations, including a collaboration with
the U.S. government, Bavarian Nordic has developed a portfolio of vaccines for
infectious diseases, including the non-replicating smallpox vaccine,
IMVAMUNE(®), which is stockpiled for emergency use by the United States and
other governments. The vaccine is approved in the European Union (under the
trade name IMVANEX(®)) and in Canada. Bavarian Nordic and its partner Janssen
are developing an Ebola vaccine regimen, which has been fast-tracked, with the
backing of worldwide health authorities, and a vaccine for the prevention and
treatment of HPV. Additionally, in collaboration with the National Cancer
Institute, Bavarian Nordic has developed a portfolio of active cancer
immunotherapies, including PROSTVAC(®), which is currently in Phase 3 clinical
development for the treatment of advanced prostate cancer. The company has
partnered with Bristol-Myers Squibb for the potential commercialization of
PROSTVAC. For more information visit www.bavarian-nordic.com or follow us on
Twitter (at)bavariannordic.
Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control, that
could cause actual results to differ materially from the results discussed in
the forward-looking statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance and/or other
information that is not historical information. All such forward-looking
statements are expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking statements. We
undertake no obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made, except as
required by law.
Contacts
Rolf Sass Sørensen
Vice President Investor Relations (EU)
Tel: +45 61 77 47 43
Seth Lewis
Vice President Investor Relations (US)
Tel: +1 978 341 5271
Company Announcement no. 26 / 2016
2016-26-en:
http://hugin.info/100065/R/2040125/761831.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 13.09.2016 - 08:01 Uhr
Sprache: Deutsch
News-ID 494318
Anzahl Zeichen: 4291
contact information:
Town:
Kvistgård
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic Issues Financial Calendar for 2017"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
